For decades, metformin has been a cornerstone treatment for type 2 diabetes, known primarily for controlling blood sugar through effects on the liver and gut. New research, however, uncovers an unexpected player in the drug’s action: the brain. Scientists at Baylor College of Medicine, alongside international collaborators, have found that a protein called Rap1 in the brain’s ventromedial hypothalamus (VMH) is crucial for metformin’s blood sugar-lowering effects.
Metformin has long been used to reduce glucose production in the liver and to act through the gut. While these pathways explain much of its activity, they do not fully capture the drug’s effects. Researchers suspected the brain might contribute to its anti-diabetic effects because it is a key regulator of overall glucose metabolism.
Rap1 protein’s central role
The team focused on Rap1, a small protein in the VMH, and discovered that metformin’s ability to lower blood sugar at clinically relevant doses depends on turning off this protein. Using genetically modified mice lacking Rap1 in the VMH, scientists found that low doses of metformin no longer reduced blood sugar. Other diabetes medications, including insulin and GLP-1 agonists, remained effective in these mice, highlighting Rap1’s unique role in metformin’s mechanism.
To further confirm the brain’s involvement, researchers injected extremely small doses of metformin directly into the brains of diabetic mice. The result was a significant drop in blood sugar, even at concentrations thousands of times lower than typical oral doses.
Specific neurons activated by metformin
Within the VMH, SF1 neurons were identified as key mediators of metformin’s brain action. Brain samples showed that these neurons became active only when Rap1 was present, confirming that the protein is essential for switching on the brain cells that regulate blood sugar.
This discovery demonstrates that metformin’s effects are not limited to the liver or gut. While these organs require high doses of the drug, the brain responds to much lower levels, emphasizing a previously unrecognized mechanism in diabetes treatment.
Implications for future therapies
While some anti-diabetic drugs act on the brain, metformin’s long-standing use suggests it has been engaging this pathway all along. Researchers say this insight could lead to new treatments that directly target Rap1 signaling in the brain. Additionally, metformin has other known health benefits, including slowing brain aging, and scientists plan to investigate whether the same Rap1 pathway contributes to these effects.
This research represents a major shift in understanding how a decades-old drug works and may inspire innovative strategies to improve diabetes care, potentially making therapies more efficient and targeted.
Source: Times of India
Leave a Reply